SynthesisInternational wound journal2021
Management of incontinence-associated dermatitis: A systematic review of monetary data.
Synthesis in International wound journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Risk factors and prevalence of incontinence-associated dermatitis in elderly patients: a meta-analysis and systematic review.BMC geriatrics · 2026Pooled it
- Prognostic factors for the development of incontinence-associated dermatitis (IAD): A systematic review.International wound journal · 2024Pooled it
- Management of incontinence-associated dermatitis: A systematic review of monetary data.International wound journal · 2021Pooled it
- The estimated economic burden of urinary incontinence-related complications in older adults Canada.The Canadian journal of urology · 2026Review
- Influence of Sociodemographic Factors and Incontinence Care Practices on the Development of Incontinence-Associated Dermatitis.Journal of clinical medicine · 2026Article
- Quercetin alleviates incontinence-associated dermatitis via IKK/NF-κB pathway.Scientific reports · 2026Article
- Evaluation of Nurses' Knowledge of Incontinence-Associated Dermatitis Among Acute Care Nurses: A Multi-Center Cross-Sectional Study.Health science reports · 2025Article
- Nursing-centered development of an AI-based decision support system in pressure ulcer and incontinence-associated dermatitis management - a mixed methods study.BMC nursing · 2025Article
- Clinical nurses' knowledge, attitudes and practices regarding incontinence-associated dermatitis: A cross-sectional study from China.PloS one · 2025Article
- Understanding the Relationship Between Chinese Nurses' Attitudes Toward Incontinence-Related Dermatitis and Achievement Motivation Through a Person-Centered Method: A Theory-Driven Cross-Sectional Study.Journal of nursing management · 2025Article
- Article
- Article
- POWER: an open, single-arm, post-market clinical trial using the TENA SmartCare Change Indicator in a home environment.Archives of medical science : AMS · 2023Article
- Bacterial invasion into the epidermis of rats with sodium lauryl sulphate-irritated skin increases damage and induces incontinence-associated dermatitis.International wound journal · 2023Article
- Establishment of incontinence-associated dermatitis rat models and assessment of the therapeutic effects of zinc oxide, painless skin protective film and silicone dressing.Experimental and therapeutic medicine · 2021Article
- Prevention and Care for Incontinence-Associated Dermatitis Among Older Adults: A Systematic Review.Journal of multidisciplinary healthcare · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The objective was to systematically review monetary data related to management of incontinence-associated dermatitis (IAD) in an adult population. Six electronic databases were searched: MEDLINE, CINAHL, Web of Science, EMBASE, The Cochrane Library and EconLit. The search string combined index terms and text words related to IAD and monetary data. The quality of the articles was assessed using the consensus on Health Economic Criteria. Results were synthesised narratively because of methodological heterogeneity. Nine studies were included. Only direct medical costs were reported. The product cost per application for prevention ranged between $0.05 and $0.52, and for treatment between $0.20 and $0.35. The product cost per patient/day for prevention ranged between $0.23 and $20.17. The product cost of IAD prevention and treatment per patient/day ranged between $0.57 and $1.08. The cost to treat IAD did not consider the treatment of secondary infection. The calculation of labour cost and total cost differed considerably between studies. Summarising monetary data is a challenge because of heterogeneity in currencies, settings, samples, time horizons, health- and cost outcome valuation, IAD definition and measurements, and included costs. Procedures for health economic evaluations are to be clarified to guarantee valid interpretation and comparison with other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.